| Literature DB >> 32535501 |
Ingo Kleiter1, Ilya Ayzenberg2, Joachim Havla3, Carsten Lukas4, Iris-Katharina Penner5, Christine Stadelmann6, Ralf A Linker7.
Abstract
The conversion of relapsing-remitting multiple sclerosis (RRMS) to secondary progressive MS (SPMS) cannot be defined by a sharp threshold determined by event-based measures, but rather represents a gradual process. In consequence, there may exist a transitional phase between RRMS and clearly established SPMS. So far, transitional MS has been poorly characterized in terms of patient properties, course of disease and therapeutic interventions that may delay conversion to SPMS. Furthermore, the pathogenesis of transitional MS is incompletely understood, and no definitive imaging or laboratory test informs when exactly a patient has entered the transitional MS phase. Here we review the current knowledge and evidence characterizing the transitional phase of MS and propose potential designs and criteria for a prospective clinical study in patients with transitional MS.Entities:
Keywords: Biomarker; Disease course; Disease modifying therapy; Progressive multiple sclerosis; Trial design
Mesh:
Year: 2020 PMID: 32535501 DOI: 10.1016/j.msard.2020.102242
Source DB: PubMed Journal: Mult Scler Relat Disord ISSN: 2211-0348 Impact factor: 4.339